PKPhuripong Kijdamrongthum

Phuripong Kijdamrongthum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Phuripong Kijdamrongthum has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Proton Pump Inhibitors Prescribing Behaviors and Rationalization Strategies Among Healthcare Providers in Southeast Asia

    by Duc Trong Quach, Tien Manh Huynh, Augusto Jose G. Galang, Hang Viet Dao, Sakkarin Chirapongsathorn, Phuripong Kijdamrongthum, Rahela Ambaras Khan, Andrew Ming‐Liang Ong, Wee Kooi Cheah, Kalwinder Singh Khaira, et al.

    Despite widespread use, real‐world evidence regarding proton pump inhibitor (PPI) prescribing and rationalization practices in Southeast Asia (SEA) remains limited; therefore, we aimed to characterize current prescribing behaviors and rationalization strategies among healthcare professionals in the region. The SEA PPI Rationalisation Working Group developed and disseminated an online questionnaire via professional networks across SEA to collect data on respondent demographics, PPI prescribing practices, and rationalization approaches; instrument reliability testing produced a Cronbach's α of 0.799 and content validity was confirmed by a panel of 10 gastroenterology experts with complete agreement on relevance and clarity (I‐CVI, kappa, SCVI/Ave = 1.0). K‐mode clustering was applied to delineate prescribing patterns. Of 869 responses received, 763 valid entries were analyzed (response rate 87.8%), 49% of whom were gastroenterologists. PPIs were most frequently prescribed for gastroesophageal reflux disease (67.8%) and peptic ulcer disease (43.8%); 48.9% of respondents reported long‐term PPI use, while 59.2% reported reassessment of indications at every follow‐up visit. Common rationalization strategies comprised dose tapering (46.8%), on‐demand administration (45.9%), and step‐down to antacids or alginates (44.8%). Cluster analysis identified two distinct prescriber profiles: proactive prescribers ( n = 326, 42.7%), who adhered to clinical guidelines, implemented individualized dosing, and routinely reassessed therapy; and conservative prescribers ( n = 437, 57.3%), who employed PPIs more restrictively and engaged less frequently in rationalization. The considerable variability in PPI prescribing and rationalization practices across SEA underscores the need for a regional consensus to promote evidence‐based practice.

  • Open Access

    Rationalizing Proton Pump Inhibitor Use: Southeast Asia Consensus Recommendations

    by Somchai Leelakusolvong, Tju Siang Chua, Duc Trong Quach, Andrew Ming‐Liang Ong, Ari Fahrial Syam, Augusto Jose G. Galang, Wee Kooi Cheah, Hang Viet Dao, Jose D. Sollano, Kalwinder Singh Khaira, et al.

    Background and Aim: Proton pump inhibitors (PPIs) are integral to managing many gastrointestinal conditions. However, the prevalent inappropriate PPI prescription across Southeast Asia (SEA) is concerning. Given the absence of locally tailored recommendations to inform clinical practice, this consensus document aims to provide recommendations for PPI rationalization to healthcare providers in the region. Methods: The SEA PPI Rationalization Working Group is steered by 14 experts practicing across Malaysia, Thailand, Singapore, Vietnam, the Philippines, and Indonesia. The experts convened to review existing evidence and develop recommendations and to conduct an anonymous voting as per the modified Delphi method. Results: Twenty statements were formulated, focusing on areas of (i) extent and impact of PPI overprescription (four statements), (ii) benefits and barriers to PPI rationalization (two statements), (iii) START/STOPP criteria for PPI (nine statements), and (iv) PPI rationalization strategies (five statements). The consensus document underscores the widespread inappropriate long‐term PPI prescription across SEA, which may have adverse clinical outcomes. Although rationalizing PPI use may be beneficial, the experts acknowledge the challenges of implementing PPI rationalization. The experts also outlined specific indications to guide PPI initiation and advised regular review to rationalize a PPI when no longer indicated. This is followed by PPI rationalization strategies, including shared decision‐making, prescribing alginate as a rescue therapy in gastroesophageal reflux disease, and further evaluation for reinitiation of PPI when clinically warranted. Conclusions: This consensus document serves to improve PPI prescribing and deprescribing practices in SEA and to provide recommendations on rationalization strategies.


  • Open Access

    Proton Pump Inhibitors Prescribing Behaviors and Rationalisation Strategies among Healthcare Providers in the Southeast Asia

    by Duc Trong Quach, Tien Manh Huynh, Augusto Jose G. Galang, Hang Viet Dao, Sakkarin Chirapongsathorn, Phuripong Kijdamrongthum, Rahela Ambaras Khan, Andrew Ming-Liang Ong, Wee Kooi Cheah, Kalwinder Singh Khaira, et al.

    SUMMARY: Background: Despite its widespread use, real-world evidence on proton pump inhibitor (PPI) prescribing and rationalisation practices in Southeast Asia (SEA) remains limited. This study aimed to investigate current prescribing behaviors and rationalisation strategies among SEA healthcare professionals. Methods: The SEA PPI Rationalisation Working Group designed and disseminated an online survey across SEA via professional networks. The questionnaire included sections on demographics, PPI prescribing habits, and rationalisation strategies. Reliability testing of the questionnaire yielded a Cronbach’s alpha of 0.799. Content validity was confirmed by a panel of 10 gastroenterology experts, with perfect agreement on relevance and clarity (I-CVI, kappa, SCVI/Ave = 1.0). K-mode clustering was used to explore prescribing patterns. The main outcome was the identification of prescribing patterns and rationalisation strategies for long-term PPI use. Findings: Among the 869 responses received, 763 valid entries were analysed (response rate: 87.8%), with 49% of the respondents being gastroenterologists. PPIs were most prescribed for gastroesophageal reflux disease (67.8%) and peptic ulcer disease (43.8%). Long-term PPI use was reported by 48.9% of the participants, while 59.2% reported reassessing indications at every follow-up visit. Rationalisation strategies included dose tapering (46.8%), on-demand use (45.9%), and step-down to antacids or alginates (44.8%). Cluster analysis identified two profiles: proactive prescribers (n=326, 42.7%) who followed clinical guidelines, applied individualised dosing, and routinely reassessed therapy, and conservative prescribers (n=437, 57.3%) who used PPIs more restrictively and rationalised less frequently. Interpretation: Marked variability in PPI prescribing and rationalisation across SEA highlights the need for regional consensus to support evidence-based practice. Funding: This study was supported by Reckitt Benckiser (Singapore) Pte Ltd ., which provided funding for article processing charge Evidence before this study: Although proton pump inhibitors (PPIs) are widely prescribed across Southeast Asia (SEA), there is limited real-world evidence examining the prescribing behaviors and rationalisation practices within the region. Previous research predominantly focused on Western countries and raised concerns regarding the over-prescription and prolonged use of PPIs. However, no studies have comprehensively addressed the regional variability in PPI prescribing or the strategies employed to rationalise their use in SEA. Added value of this study: This study provides the first region-wide analysis of PPI prescribing practices and rationalisation strategies in SEA. By employing cluster analysis, the study identifies two distinct prescriber profiles: proactive prescribers, who follow clinical guidelines and individualise treatment, and conservative prescribers, who use PPIs more restrictively and apply rationalisation strategies less frequently. The study offers critical insights into the current prescribing landscape in SEA, highlighting the need for evidence-based regional guidelines to optimise PPI use. Implications of all the available evidence: The findings suggest that significant variability in PPI prescribing exists across SEA, underscoring the necessity for region-specific guidelines. Policymakers should use these insights to inform evidence-based clinical guidelines for PPI use and rationalisation. Additionally, future research should explore the effectiveness of rationalisation strategies and identify barriers to their implementation within diverse healthcare systems in SEA.


  • Randomised clinical trial: the effects of pregabalin vs placebo on functional dyspepsia

    by Isariyaphong Kotikula, Nithi Thinrungroj, Kanokwan Pinyopornpanish, Phuripong Kijdamrongthum, Apinya Leerapun, Taned Chitapanarux, Satawat Thongsawat, Ong‐Ard Praisontarangkul

    Summary: Background: Currently, central neuromodulators are among the therapeutic options for the treatment of functional dyspepsia (FD). Pregabalin, a gabapentinoid, is a neuromodulator that could potentially improve visceral hypersensitivity in FD patients.Aim: To assess the efficacy and safety of pregabalin for the treatment of FDMethods: We performed a randomised placebo‐controlled study including FD patients who did not respond to proton pump inhibitors. Patients were randomly assigned to receive pregabalin (75 mg daily) or placebo for 8 weeks. The primary outcome was an adequate relief response rate. The secondary outcomes were improvement in quality of life, pain scores in divided categories, and safety profile.Results: Of 72 patients enrolled, 34 received pregabalin and 38 received placebo. The self‐reported adequate relief rates in the pregabalin and placebo groups were 70.6% and 42.1% at week 4 (P = 0.02), and 70.6% and 44.7% at week 8 (P = 0.03), respectively. The reduction in global symptoms in the pregabalin and placebo groups were 11.7 ± 10.6 and 3.7 ± 8.9 points at week 4 (P < 0.01) and 15.1 ± 12.2 and 8.0 ± 10.2 points at week 8 (P = 0.01), respectively. Pregabalin improved the overall quality of life (P = 0.03). The most common adverse event with pregabalin was dizziness, occurring in 51.6% of patients.Conclusions: Pregabalin led to significant alleviation of dyspeptic symptoms, especially in patients with predominant epigastric pain .Thaiclinicaltrials.org #TCTR20200404002.